• We are proud to be working with Dr. Brian Cunniff and his lab at the University of Vermont to further scientific research for mesothelioma.

    Visit Cunniff Lab 
  • RS Oncology, the biotech company located in Cambridge, MA is pioneering treatment and novel therapies through global partnerships.

    Check out RS Oncology 

Supporting the Science

Mitochondrial redox status as a therapeutic target in cancer

In order to grow uncontrollably tumor cells must generate an abundance of energy and cellular building blocks to grow. This excessive growth comes at a cost of increased waste products associated with abundant growth. Tumor cells are exquisitely vulnerable to the build up of toxic waste products and have developed systems to combat these damaging toxic molecules. This provides a window for therapeutic intervention exploitable through targeting these waste removal systems. We are investigating metabolism in malignant mesothelioma and ovarian cancer and have identified promising new compounds that selectively kill tumor cells through redox-dependent mechanisms.